Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Strengthening National Capacity in Malaria and Other Infectious Disease Operations Research, Funding Opportunity Announcement (FOA) CK09-004, Initial Review, 33450-33451 [E9-16461]
Download as PDF
<![CDATA[
33450
Federal Register / Vol. 74, No. 132 / Monday, July 13, 2009 / Notices
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
Advisory Committee for Women’s
Services; Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given of a Web-based
meeting of the Substance Abuse and
Mental Health Services Administration
(SAMHSA) Advisory Committee for
Women’s Services on July 29, 2009 from
2 p.m. to 4:30 p.m. The meeting is open
to the public and will include an update
on current and emerging research on
women-specific substance use and
mental health issues.
ACWS members and invited
presenters will participate in this
meeting through remote internet
connection. On-site attendance by the
public will be limited to space available.
The meeting can also be accessed by the
public via teleconference. To obtain
teleconference call-in numbers and
access codes, to make arrangements to
attend on-site, or to request special
accommodations for persons with
disabilities, please communicate with
Ms. Nevine Gahed, Designated Federal
Official (see contact information below).
Substantive meeting information and
a roster of Committee members may be
obtained either by accessing the
SAMHSA Committees’ Web site at
https://nac.samhsa.gov/
WomenServices/index.aspx, or by
contacting Ms. Gahed. The transcript for
the meeting will also be available on the
SAMHSA Committees’ Web site within
three weeks after the meeting.
Committee Name: SAMHSA Advisory
Committee for Women’s Services.
Date/Time/Type: Wednesday, July 29,
2009, from 2 p.m. to 4:30 p.m.: Open.
Place: 1 Choke Cherry Road, Sugarloaf
Conference Room, Rockville, Maryland
20857.
Contact: Nevine Gahed, Designated
Federal Official, SAMHSA Advisory
Committee for Women’s Services, 1
Choke Cherry Road, Room 8–1112,
Rockville, Maryland 20857, Telephone:
(240) 276–2331; FAX: (240) 276–2220
and E-mail:
nevine.gahed@samhsa.hhs.gov.
VerDate Nov<24>2008
18:36 Jul 10, 2009
Jkt 217001
Dated: July 6, 2009.
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
[FR Doc. E9–16457 Filed 7–10–09; 8:45 am]
Dated: July 7, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–16460 Filed 7–10–09; 8:45 am]
BILLING CODE 4162–20–P
Dated: June 16, 2009.
Charlene Frizzera,
Acting Administrator, Centers for Medicare
& Medicaid Services.
[FR Doc. E9–16677 Filed 7–10–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Capacity
Building Assistance (CBA) To Improve
the Delivery and Effectiveness of
Human Immunodeficiency Virus (HIV)
Prevention Services for High-Risk and/
or Racial/Ethnicity Minority
Populations, Program Announcement
Number PS09–906, Initial Review
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Strengthening
National Capacity in Malaria and Other
Infectious Disease Operations
Research, Funding Opportunity
Announcement (FOA) CK09–004, Initial
Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 8:30 a.m.–5:30 p.m., July
28, 2009 (Closed).
Place: CDC, Corporate Square Campus, 8
Corporate Boulevard, Atlanta, Georgia 30329.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include an initial review, discussion, and
evaluation of applications received in
response to ‘‘Capacity Building Assistance
(CBA) to Improve the Delivery and
Effectiveness of Human Immunodeficiency
Virus (HIV) Prevention Services for HighRisk and/or Racial/Ethnicity Minority
Populations, PS09–906.’’ The meeting was
initially held June 15–18, 2009. A reviewer
conflict of interest was confirmed after the
meeting commenced and a reviewer for
another application was unable to participate
due to sudden illness; therefore, the panel
will be reconvened to review the affected
applications.
Contact Person for More Information:
Monica Farmer, M.Ed., Public Health
Analyst, Strategic Science and Program Unit,
Office of the Director, Coordinating Center
for Infectious Diseases, CDC, 1600 Clifton
Road, NE., Mailstop E–60, Atlanta, GA
30333, Telephone: (404) 498–2277.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 2:30 p.m.–4:30 p.m.,
July 28, 2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the initial review,
discussion, and evaluation of
‘‘Strengthening National Capacity in
Malaria and Other Infectious Disease
Operations Research, Funding
Opportunity Announcement (FOA)
CK09–004.’’ This meeting was initially
held June 1, 2009. A reviewer was
unable to participate unexpectedly and
the meeting was held in the absence of
the required quorum; therefore, the
panel will be reconvened to review the
application received in response to the
announcement.
FOR FURTHER INFORMATION CONTACT:
Wendy Carr, PhD, CDC, 1600 Clifton
Road, NE., Mailstop D60, Atlanta, GA
30333, Telephone: (404) 498–2276.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
E:\FR\FM\13JYN1.SGM
13JYN1
Federal Register / Vol. 74, No. 132 / Monday, July 13, 2009 / Notices
Dated: July 7, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–16461 Filed 7–10–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0284]
Food and Drug Administration
Regulation and Licensure of Whole
Blood and Blood Components,
Including Source Plasma; Public
Workshop; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION: Notice of public workshop;
request for comments.
The Food and Drug Administration
(FDA) is announcing a public workshop
entitled ‘‘FDA Regulation and Licensure
of Whole Blood and Blood Components,
Including Source Plasma.’’ The purpose
of the workshop is to educate industry
on the licensure requirements and
license application procedures for
Whole Blood and blood components,
including Source Plasma, and request
comments on this topic.
Dates and Time: The public workshop
will be held on September 15, 2009,
from 8 a.m. to 5:30 p.m. and September
16, 2009, from 8 a.m. to 4 p.m.
Location: The public workshop will
be held at The Universities at Shady
Grove Conference Center, 9630
Gudelsky Dr., Bldg. 1, Rockville, MD
20850.
Contact Person: Rhonda Dawson,
Center for Biologics Evaluation and
Research (HFM–302), Food and Drug
Administration, 1401 Rockville Pike,
suite 400N, Rockville, MD 20852–1448,
301–827–6129, FAX: 301–827–2843, email: rhonda.dawson@fda.hhs.gov.
Registration: Mail, fax, or e-mail your
registration information (including
name, title, firm name, address,
telephone, and fax numbers) to the
contact person (see Contact Person) by
August 17, 2009. There is no registration
fee for the public workshop. Early
registration is recommended because
seating is limited. Registration on the
day of the public workshop will be
provided on a space available basis
beginning at 7:30 a.m.
If you need special accommodations
due to a disability, please contact
Rhonda Dawson (see Contact Person) at
least 7 days in advance of the workshop.
VerDate Nov<24>2008
18:36 Jul 10, 2009
Jkt 217001
Comments: All individuals wishing to
submit questions to be addressed at the
public workshop should submit written
or electronic comments by August 17,
2009, to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. Submit a single
copy of electronic comments or two
paper copies of any mailed comments,
except that individuals may submit one
paper copy. Comments are to be
identified with the docket number
found in brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
FDA held
a licensing workshop for blood
establishments in 1995 to advise the
blood and plasma industry on how to
apply for a U.S. license to distribute
Whole Blood and blood components,
including Source Plasma, in interstate
commerce. This workshop will build
upon the 1995 workshop and provide
regulatory updates since the last
workshop. The workshop will include
presentations by FDA on the following
topics: (1) Requirements for licensure
and applicable regulations and guidance
documents for Whole Blood and blood
components, including Source Plasma;
(2) managed review process; (3) review
criteria for various submissions; (4)
blood establishment registration and
product listing requirements; (5)
inspections of blood establishments
pending licensure and approval; and (6)
requests for exceptions or use of
alternative procedures to the
regulations. The workshop will include
a question and answer session with
workshop participants.
Transcripts: Transcripts of the public
workshop may be requested in writing
from the Freedom of Information Office
(HFI–35), Food and Drug
Administration, 5600 Fishers Lane, rm.
6–30, Rockville, MD 20857,
approximately 15 working days after the
public workshop at a cost of 10 cents
per page. A transcript of the public
workshop will be available on the
Internet at https://www.fda.gov/cber/
minutes/workshop-min.htm.
SUPPLEMENTARY INFORMATION:
33451
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 8 a.m.–4 p.m., July 29,
2009.
Place: CDC, Tom Harkin Global
Communications Center, 1600 Clifton Road,
NE., Building 19, Kent ‘‘Oz’’ Nelson
Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available.
Purpose: The committee is charged with
advising the Director, CDC, on the
appropriate uses of immunizing agents. In
addition, under 42 U.S.C. Section 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children program, along with
schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines.
Matters To Be Discussed: The agenda will
include discussions related to
recommendations for use of influenza
vaccines in the prevention and control of
novel (pandemic) influenza A (H1N1); novel
H1N1 epidemiology in the United States;
novel H1N epidemiology, international
settings; modeling novel H1N1 influenza
impact and impact of vaccination;
implementation planning; vaccine
development and formulation; and the Food
and Drug Administration/Vaccines and
Related Biological Products Advisory
Committee update. Agenda items are subject
to change as priorities dictate.
Contact Person for More Information:
Antonette Hill, Immunization Services
Division, National Center for Immunization
and Respiratory Diseases, CDC, 1600 Clifton
Road, NE., Mailstop E–05, Atlanta, Georgia
30333, Telephone: (404) 639–8836, Fax: (404)
639–8905.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and Agency for Toxic
Substances and Disease Registry.
Dated: July 7, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–16657 Filed 7–10–09; 8:45 am]
Dated: July 6, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–16475 Filed 7–10–09; 8:45 am]
BILLING CODE 4160–01–S
BILLING CODE 4160–18–P
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
E:\FR\FM\13JYN1.SGM
13JYN1
]]>Agencies
[Federal Register Volume 74, Number 132 (Monday, July 13, 2009)]
[Notices]
[Pages 33450-33451]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-16461]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Strengthening National Capacity in Malaria and
Other Infectious Disease Operations Research, Funding Opportunity
Announcement (FOA) CK09-004, Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting.
Time and Date: 2:30 p.m.-4:30 p.m., July 28, 2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the initial
review, discussion, and evaluation of ``Strengthening National Capacity
in Malaria and Other Infectious Disease Operations Research, Funding
Opportunity Announcement (FOA) CK09-004.'' This meeting was initially
held June 1, 2009. A reviewer was unable to participate unexpectedly
and the meeting was held in the absence of the required quorum;
therefore, the panel will be reconvened to review the application
received in response to the announcement.
FOR FURTHER INFORMATION CONTACT: Wendy Carr, PhD, CDC, 1600 Clifton
Road, NE., Mailstop D60, Atlanta, GA 30333, Telephone: (404) 498-2276.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
[[Page 33451]]
Dated: July 7, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E9-16461 Filed 7-10-09; 8:45 am]
BILLING CODE 4163-18-P
